Efficacy responses with tildrakizumab in moderate-to-severe chronic plaque psoriasis patients with previous exposure to apremilast: Results of a pooled analysis of reSURFACE 1 and reSURFACE 2

Background: Tildrakizumab (TIL) is a high-affinity anti–IL-23p19 monoclonal antibody for the treatment of chronic plaque psoriasis. We assessed a subgroup of chronic plaque psoriasis patients who reported previous treatment with apremilast (APT), a phosphodiesterase 4 inhibitor, to evaluate its potential influence on efficacy in two large, phase 3 clinical studies of tildrakizumab.